Corporate | 3 March 2016 11:02
DGAP-News: Evotec AG / Key word(s): Conference
2016-03-03 / 11:02
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany - 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner
Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The
Netherlands, and at the 28th Annual Roth Conference in Dana Point, CA, USA.
BioCapital Europe 2016, Sofitel Legend Amsterdam The Grand in Amsterdam
Date: Wednesday, 09 March 2016, 03.00 pm CET
Venue: Sofitel Legend Amsterdam The Grand, Amsterdam, The Netherlands
Presenter: Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG
28th Annual Roth Conference, The Ritz Carlton in Dana Point, CA
Date: Tuesday, 15 March 2016, 01.00 pm PDT (9:00 pm CET)
Venue: The Ritz Carlton, Dana Point, CA, USA
Presenter: Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG
The PDF version and the direct link to the webcast of the presentation at
28th Annual Roth Conference will be provided at http://www.evotec.com/.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
---------------------------------------------------------------------------
2016-03-03 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX
End of News DGAP News Service